NCT03790228 - Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

October 1, 2020

Study Completion Date

August 31, 2021

Conditions

Non-squamous Cell Non-Small Cell Lung Cancer

Interventions

DRUG

Anlotinib Combined With Pemetrexed And Carboplatin

Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)

Trial Locations (1)

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou